The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
The Food and Drug Administration approved Eli ... the most common sleep-related breathing disorder. The weekly injection is ...
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...
The new approval is for people with moderate to severe obstructive sleep apnea who are also living with obesity. Eli Lilly estimates that is about 15-20 million adults in the U.S. Obstructive ...
MORE: Zepbound leads to more weight loss than Wegovy, Eli Lilly says Obstructive sleep apnea isn’t just an inconvenience, it’s a serious medical condition that impairs breathing and sleep quality.